Eversheds says Sun Pharmaceuticals deal represents opportunity in generics market

Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.

Lewis said: ‘This deal is a clear sign of further consolidation in the Indian generics market as companies look to increase market share, enhance growth opportunities and reduce costs.

‘As the country’s largest pharma company, it will now be particularly well placed to capitalise on the fast-growing Indian pharmaceuticals market.’